New Street Research

Provided by our team of experienced analysts, our work is idea driven, based on independence of thought, sector expertise, and firmly focussed on fundamentals and valuation.

New Street Research is an independent, partner-owned, research firm specialising in equity and debt research. Our equity research embraces the following sectors:

  • Pan European Telecom Services and Cable
  • US Telecoms, Cable, Satellite and Towers
  • Global Emerging Market Telecoms
  • Japan Telecoms
  • Asian Internet
  • Pan European Healthcare
  • Global healthcare thematic research

We provide debt research on:

  • Pan European Telecom Services and Cable


Chris Hoare
  • Chris Hoare

African Towers and Telcos IHS offers improved terms to MTN Nigeria re...

Press reports that IHS has offered improved commercial terms to MTN Nigeria regarding the 2,500 towers previously lost to ATC. This suggests that as we previously wrote there must have been a material difference in commercial terms, with the corporate governance issue secondary. Increasing evidence of competition in contract renewals is negative for Towers and positive Telcos in EM.

Jonathan Chaplin
  • Jonathan Chaplin

CHTR Quick Hit: Charter Buys Back $0.5BN of Shares in November

Advance/Newhouse filed its latest Charter ownership disclosure yesterday. The buyback amount was nearly in-line with our expectation. We are keeping our 4Q23 share repurchase estimate unchanged.

Chris Hoare
  • Chris Hoare

Axiata (Buy, TP: MYR 5.7, +145%) Highlights from Investor Day 2023

Axiata held its Investor Day in Kuala Lumpur on Wednesday and outlined plans to deliver on its 2025/26 targets; de-lever to 2.5x and grow DPS sustainably. Key themes include the delayering of XL Axiata and Link Net, market repair in Indonesia and its Frontier Markets, operational excellence and deleverage goals. See below for our brief takeaways.

US Cable M&A Update: CHTR / TWC Deal Spread Presents Compelling Opport...

​Investors are still concerned that the CHTR / TWC transaction could be blocked, as evidenced by a deal spread of 9%. The market appears to be giving the deal 50% odds of being approved. We think the market is way off the mark; this deal has high odds of approval.

Ben Rickett ... (+3)
  • Ben Rickett
  • Russell Waller
  • Shavar Halberstadt

New Street: W. Europe Mobile Tariff Tracker Nov 2019: Widespread disco...

The average package price growth in Europe remained steady at +1.9% YoY (from +2.4% YoY in October). Widespread discounting in the UK following Black Friday was offset by higher prices in Spain, Portugal and Austria.

Ben Rickett ... (+3)
  • Ben Rickett
  • Russell Waller
  • Shavar Halberstadt

New Street: W. Europe Mobile Tariff Tracker Nov 2019: Widespread disco...

The average package price growth in Europe remained steady at +1.9% YoY (from +2.4% YoY in October). Widespread discounting in the UK following Black Friday was offset by higher prices in Spain, Portugal and Austria.

Iain Johnston
  • Iain Johnston

China Internet Daily (28 August 2018)

Tencent's Wealth Management Platform Licaitong Adds Five New Money Market Funds.

Dominic Rose ... (+2)
  • Dominic Rose
  • Naresh Chouhan

Thematic - Obesity Drugs Won’t Change The World

Despite our bullish stance on Novo & the obesity drugs, in this note we aim to show the minimal impact they will have on the broader economy despite recent fears that new obesity drugs will have a material negative impact on a broad range of sectors. We show that these claims are well overblown in the near-term, with only 0.15% of the US population currently on anti-obesity drugs (AODs). Our forecasts, which point to a $50bn US market by 2030, imply that

Dominic Rose ... (+2)
  • Dominic Rose
  • Naresh Chouhan

Global CDMOs - Impact of Alzheimer's Windfall

Our unique coverage of the biggest CDMO’s allows us to quantify the financial impact on the industry of a potential Alzheimer’s windfall from Biogen’s aducanumab. As the FDA filing draws closer, Biogen are likely to be involved in intense negotiations to find alternative sources of supply. Our highly detailed analysis shows how much aducanumab will need to be produced, who the winners are likely to be, the revenue uplift they may enjoy and the NPV uplift to each player. Lonza & Samsung Bio...

James Ratzer ... (+2)
  • James Ratzer
  • Pierre FerraguÊ

EU Telecoms Sector Upgrade: Time to give the sector a fresh look – V...

European telecoms sector looks attractive – the past is not always a guide for the future: Investors and analysts have been browbeaten with generally poor trends in the European telecoms sector for many years.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch